Genmab — Januar 2020
-
@McJean og JKY kl. 14.06 og 14.10: Helt enig.
-
I alle pensionerne har jeg samme problem som nohope.
-
God morgen.
-
Daratumumab Plus Rd Sustains Responses in Transplant-Ineligible Myeloma https://www.targetedonc.com/news/daratumumab-plus-rd-sustains-responses-in-transplantineligible-myeloma
-
"....but we are looking at the possibility of re-treatment of daratumumab at this meeting. The concept of the LYNCH trial, which is looking at retreatment of daratumumab at the time of relapse or disease-progression in combination with carfilzomib. While we are going to use daratumumab in the frontline setting, we hope a future study will demonstrate that daratumumab can be reused in the subsequent lines of therapy as well."
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind